New combo therapy aims to boost survival in advanced cervical cancer
NCT ID NCT06416696
First seen Jan 11, 2026 · Last updated Jun 23, 2026 · Updated 28 times
Summary
This phase II trial is testing whether adding the immunotherapy drug toripalimab to standard chemoradiotherapy can improve outcomes for patients with high-risk locally advanced cervical cancer. About 57 participants will receive the combination, followed by maintenance toripalimab. The main goal is to see if this approach increases the two-year survival rate without the cancer progressing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100021, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Toripalimab (a PD-1 inhibitor) combined with cisplatin chemotherapy and radiation therapy
What this could lead to
If successful, this could offer a more effective treatment option for high-risk cervical cancer patients, potentially improving survival rates and making therapy more accessible.
What could go wrong
This is a small, early-phase (phase II) study with only 57 participants, so results may not apply to everyone. Side effects from the drug combination are possible, and the trial is not yet complete.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.